Abstract Periconceptional folate intake reduces both the occurrence and recurrence risk of neural tube defects. Plasma homocysteine levels can be elevated in mothers of a child with a neural tube defect, suggesting a dysfunctional folate metabolism. Very recently we showed that a common 677C→T mutation in the 5,10-methylene tetrahydrofolate reductase gene, causing thermolability of the enzyme, is a risk factor for spina bifida offspring. Restriction enzyme analysis of the genomic 5,10-methylene tetrahydrofolate reductase polymerase chain reaction fragment revealed a significantly higher prevalence of a +/+ genotype among spina bifida patients and their mothers. The risk for spina bifida offspring is the strongest if both the mother and her child have the mutation in the homozygous state. Enzymatic analysis showed that homozygosity for the 677C→T mutation causes a decreased 5,10-methylene tetrahydrofolate reductase activity, resulting in elevated plasma homocysteine and red blood cell folate levels and lowered plasma folate and cysteine values. This extended study demonstrates that a nucleotide substitution in the coding region of 5,10-methylene tetrahydrofolate reductase, resulting in reduced activity and an impaired homocysteine and folate metabolism, is a genetic risk factor for spina bifida.
Introduction
Meningo(myelo)cele, encephalocele, and anencephaly are the most common severe congenital malformations. These malformations arise due to failure of closure of the neural tube and are referred to as neural tube defects (NTD). Periconceptional folate administration reduces the occurrence and recurrence risk of NTD [1, 2] . Both genetic and environmental factors, such as maternal nutritional status, have been proposed to affect the risk for NTD [3] . The folate levels in mothers of a child with a NTD are not deficient but in the lower range of control levels [4] . We [5] and others [6] have demonstrated that elevated plasma homocysteine levels, indicating the presence of an abnormal folate metabolism, are present in mothers of a child with a NTD.
Reduced activity of 5,10-methylene tetrahydrofolate reductase (MTHFR), a key enzyme in the folate-dependent homocysteine metabolism, is associated with elevated plasma homocysteine levels [7, 8] . MTHFR catalyzes the reduction of 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for the methylation of homocysteine to methionine. This report is an extension of our previous study in which we showed that the 677C→T mutation in the MTHFR gene is a risk factor for spina bifida (SB) offspring [9] , which has recently been confirmed by others [10] . The 677C→T mutation causes a redistribution of folates, namely elevated red cell folate and lowered plasma folate levels, and an elevation of homocysteine levels in family members (pa- Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring tients and their parents) with SB offspring. This mutation explains a substantial part of the observed elevated homocysteine levels in mothers of a child with SB.
In addition to the prevalence of the 677C→T mutation, we determined the activities of MTHFR in isolated lymphocytes and examined the relation of the 677C→T mutation with the plasma homocysteine, cysteine, vitamin B 12 , red cell folate, and plasma folate levels in families with SB offspring.
Patients and methods
Patients with SB and their parents were recruited by BOSK, a Dutch society for patients with central nervous system defects and their parents [9] . The study group consisted of families with sporadic SB offspring, namely 70 mothers (mean age 45.7±11.7 years), 60 fathers (mean age 47.6±11.6 years), and 55 children with SB (mean age 23.3±11.6 years).
The control group consisted of volunteers recruited from a general practice in The Hague [11] . Individuals from the practice, aged 20-90 years, were invited to participate in a health survey of risk factors for cardiovascular disease. The 207 unrelated persons that agreed to take part were used as control group in the present study (mean age 53.0±12.1 years). None of the controls suffered from SB or had an affected child.
The investigated mutation in the MTHFR gene is a C to T substitution at base pair 677 altering an alanine to a valine residue. This mutation creates a HinfI site, designated (+), allowing restriction site analysis [12] . The prevalence of this mutation was investigated by polymerase chain reaction of genomic DNA and restriction enzyme digestion with HinfI, followed by agarose gel electrophoresis. The prevalence of the + allele in the control group was used to determine the expected prevalence of the genotype of a control mother and that of her child.
MTHFR activities were measured in lymphocytes, which were isolated from heparinized blood [9] . The MTHFR activity was determined by a radiochemical assay in its physiological reverse direction [8] . Activities were determined after incubation at 37°C and after heat inactivation for 5 min at 46°C. In this study MTHFR activity was considered to be thermolabile when the residual activity after heat inactivation at 46°C was below 37% of the specific activity. MTHFR activities were determined in 110 of the controls.
Homocysteine and cysteine concentrations were determined in EDTA plasma by HPLC with fluorescence detection [13] . Folate and vitamin B 12 levels of heparinized plasma and folate levels of red cells were determined by using the Dualcount Solid Phase Boil Radioassay (Diagnostic Products, Los Angeles, Calif, USA).
Odds ratios [14] and 95% confidence intervals (95% CI) were calculated to estimate the relative risk of the homozygous mutation. Results are expressed as the mean value ± standard deviation (SD). One-way analysis of variance was used to calculate the statistical significant differences between the mean values of the three different genotypes, followed by pairwise Wilcoxon rank sum tests. P values were two-tailed, and P<0.05 was considered statistically significant. Correlation was determined by Spearman's correlation with a two-tailed 95% confidence interval.
Results
Genetic analysis revealed homozygosity for the alanine to valine substitution (+/+) in 4.8% of the controls versus 15.7% of the mothers, 10.0% of the fathers, and 12.7% of the affected children of the families with SB offspring, as reported previously [9] . The determined odds ratios were 3.7 (95% CI: 1.5-9.1); 2.2 (95% CI: 0.8-6.3), and 2.9 (95% CI: 1.0-7.9) for mothers, fathers and children, respectively, versus controls. The odds ratio increased to 4.1 (1.5-11.1) if the mother had a +/+ genotype and her child a +/-genotype, and even to 6.1 (95% CI:1.0-35.5) if both the mother and her child have a +/+ genotype ( Table 1) . Heterozygosity for the 677C→T mutation was observed in 41.5% of the controls versus 38.6% of the mothers, 41.7% of the fathers and 47.3% of the SB patients. The wild type (-/-) was present in 53.6% of the controls, 45.7% of the mothers, 48.3% of the fathers, and 40.0% of the affected children. Table 2 documents the relationship between presence of the 677C→T mutation, MTHFR activity and plasma homocysteine levels. The mean MTHFR activities were lowered in individuals with the mutation in homozygous (+/+) and even in heterozygous (+/-) state. In virtually all studied subjects the +/+ genotype matched with thermolabile enzyme activity [9] . The measured MTHFR activities were independent of age (data not shown). Homocysteine levels were elevated in controls, mothers, and fathers with the +/+ genotype compared to +/-and -/-genotypes, but not in the children (Table 2) . Since the plasma homocysteine levels are thought to increase with age [15] [16] [17] , the mean homocysteine values of affected children with a +/+ genotype were not increased, probably due to their lower mean age than that of the children with a +/-or -/-genotype. The mean ages among children with the different genotypes were, respectively: +/+, 14.6 (±4.1); +/-, 23.9 (±12.5); and -/-, 25.3 (±11.3) years. Since no reference data are available for homocysteine levels of children, we can draw no definite conclusions about the homocysteine levels of the children homozygous for the mutation.
Homozygosity for the 677C→T mutation resulted in significantly higher plasma homocysteine levels (17.1±11.5 µmol/l) than in heterozygous individuals (13.2±3.1 µmol/l) or wild-type individuals (13.4± 3.4 µmol/l). We also observed significantly higher red cell folate levels of individuals with a +/+ genotype (643±186 nmol/l) than in individuals with a +/-(517± 182 nmol/l) or -/-(541±188 nmol/l) genotype. The plasma folate levels of individuals homozygous for the 677C→T mutation (9.5±3.1 nmol/l) were significantly lower than those of individuals heterozygous for the 677C→T mutation (12.8±6.7 nmol/l) or individuals with the wild type (12.8±6.5 nmol/l). The plasma cysteine levels of individuals with a +/+ genotype (201± 28.9 µmol/l) were also significantly lower than in individuals with a +/-(211±29.8 µmol/l) or -/-(215± 29.7 µmol/l) genotype. The 677C→T mutation had no effect on the plasma vitamin B 12 levels [9] . Figure 1 shows the relationship between homocysteine and folate in plasma by MTHFR genotype. There is a correlation coefficient of -0.4 between the homocysteine and folate levels in plasma of individuals homozygous for the mutation. We observed no correlation between plasma homocysteine and folate levels of individuals with a +/-or a -/-genotype.
Discussion
The 677C→T mutation in the MTHFR gene is the first identified genetic risk factor for SB in man. The data from restriction site analysis reveal that not only homozygosity for the mutation (+/+) of the mothers but also the +/+ genotype of the affected children is a risk factor for SB. The risk for SB offspring increases if both the mother and her child have a +/+ genotype, indicating that not only the genotype of the mother but also that of the child contributes to the risk for SB offspring.
The odds ratios of 2.9 in patients and 3.7 in their mothers are modest, but from the point of view of general health care the observed risk factors are of great importance because of the high prevalence of homozygous mutants of about 5% in the general population.
The 677C→T mutation causes an alanine to valine substitution in the MTHFR protein. This amino acid change results in decreased MTHFR activity in both the homozygous and the heterozygous state. The product of the MTHFR catalyzed reaction, 5-methyltetrahydrofolate, is the predominant circulatory form of folate, whereas the noncirculating forms of folate such as the substrate of MTHFR, methylene tetrahydrofolate, are mainly inside the cell. The effect of decreased MTHFR activity on folate metabolism, due to the 677C→T mutation, is elegantly reflected by elevated red cell and decreased plasma folate levels in individuals homozygous for this mutation. Individuals with a +/+ genotype demonstrate elevated plasma homocysteine at folate levels, where those with a +/-or -/-genotype have normal plasma homocysteine levels, showing a defective homocysteine methylation to methionine. In order to obtain adequate 5-methyltetrahydrofolate levels for homocysteine metabolism +/+ individuals obviously need a higher dietary intake of folate.
Homocysteine methylation by 5-methyltetrahydrofolate to methionine is regulated by S-adenosylmethionine (AdoMet) at the level of MTHFR [18] . AdoMet is an allosteric inhibitor of the enzyme. AdoMet donates its Table 2 Relationships between MTHFR genotype, specific enzyme activity, and plasma homocysteine levels in controls and families with SB offspring. The mean specific MTHFR activities (±SD) are given in nmol CH 2 methyl group in over a hundred different methyltransferase catalyzed reactions, including DNA-methylation [18] . Since reduced MTHFR activity might cause reduced availability of the AdoMet precursor methionine, hypomethylation of DNA during embryogenesis may disrupt the regulation of genes involved in closure of the neural tube. This could be the underlying mechanism by which a deficient MTHFR could provoke SB or orofacial clefts. The observed decreased total plasma cysteine levels may also be explained by decreased AdoMet levels. AdoMet stimulates cystathionine synthase activity [19] . Therefore low AdoMet levels may lead to decreased conversion of homocysteine via cystathionine to cysteine.
The increased frequency of the MTHFR 677C→T mutation in mothers and their affected children indicates that this polymorphism is a genetic risk factor for SB. In addition, since folate administration may overcome the effects of reduced MTHFR activity [20] , our findings provide an explanation for the protective role of folate in the etiology of NTD.
Periconceptional folate administration reduces the occurrence and recurrence of NTD offspring by at least 72% [1, 2] . However, combination of the frequencies of the mothers and SB children indicates that the 677C→T mutation can account maximally for only 27.4% of the observed protective effect of folate (Table 1) . Hence, there may still be other defective genes present in the folate, vitamin B 12 , and/or homocysteine metabolism causing an increased risk of a SB offspring.
